Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the 2009 GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than consolidated financial performance.
Material Changes
The filing details a transaction on February 25, 2011, where Mrs. V. Whyte sold 217 Ordinary shares at a price of £11.77 per share. This sale was executed to meet tax liabilities following the vesting of a Performance Share Plan (PSP) award originally granted on February 19, 2008.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £11.77 against market data for February 25, 2011.
- Confirm the vesting schedule and tax implications of the 2008 Performance Share Plan award.
- Review the total shareholding of Mrs. V. Whyte post-transaction to assess ongoing managerial interest.